Pars plana vitrectomy and subretinal tissue plasminogen activator for large exudative submacular hemorrhage: a case series

Table 1 Characteristics of patients with large submacular hemorrhage secondary to exudative age-related macular degeneration

Case	Age (Y)	Sex	Eye	SMH		Dx	Operation		Displacement of SMH at Month 1	Post- Op	Snellen Visual Acuity
Case	Age (Y)	Sex	Eye	Duration (Day)	Extent (DD)	Dx	Gas	Anti-VEGF	Displacement of SMH at Month 1	Post- Op	Baseline	Month 1	Final
1	62	M	OD	7	5.5	PCV	C3F8	BZB	Complete	Anti-VEGF	20/400	20/200	20/80
2	68	M	OS	4	4.2	PCV	SF6	BZB	Complete	Anti-VEGF, PDT	CF	20/200	20/60
3	78	F	OD	4	5.6	AMD	C3F8	No	Complete	No	HM	20/200	20/1200
4	63	M	OS	7	4.0	N/A	SF6	No	Complete	Anti-VEGF	HM	20/200	20/200
5	76	F	OS	30	6.6	AMD	SF6	No	Partial	Anti-VEGF	CF	20/200	20/200
6	72	F	OD	30	5.2	PCV	SF6	No	Complete	PDT	20/400	20/200	20/200
7	54	M	OS	21	15.0	PCV	SF6	BZB	Complete	Anti-VEGF	HM	20/200	20/60
8	68	F	OD	9	5.0	PCV	SF6	BZB	Complete	Anti-VEGF	CF	20/120	20/60
9	61	M	OD	23	5.1	AMD	SF6	BZB	Complete	Anti-VEGF	HM	20/400	20/400

Y year, SMH submacular hemorrhage, DD disc diameter, Dx diagnosis, Anti-VEGF anti-vascular endothelial growth factor, M male, F female, OD right eye, OS left eye, PCV polypoidal choroidal vasculopathy, AMD age-related macular degeneration, C3F8 perfluoropropane, SF6 sulfurhexafluoride, BZB bevacizumab, CF counting finger, HM hand movement, PDT photodynamic therapy

ISSN: 1471-2415